“Low Leukocyte MGMT Accompanies Temozolomide-Induced Myelotoxicity in Brain Tumor Patients ”, J. Can. Res. Updates, vol. 1, no. 1, pp.  44–48, Jan. 2012, doi: 10.6000/1929-2279.2012.01.01.08.